{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:17:13Z","timestamp":1772831833123,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although Janus kinase (JAK) inhibitors have demonstrated efficacy for treating autoimmune disorders and myeloproliferative neoplasms, their efficacy in treating other types of cancer has not been clearly demonstrated. We evaluated oral ruxolitinib (15\u2009mg twice daily) with oral methylprednisolone (40\u2009mg every other day) for multiple myeloma (MM) patients with progressive disease who had received a proteasome inhibitor, lenalidomide, glucocorticosteroids and three or more prior regimens. All of the planned 29 patients had been enrolled with follow\u2010up until 28 April 2022. Median lines of prior therapy were 6 (range 3\u201312). Cytogenetics and fluorescent in situ hybridization were evaluable in 28 patients; 9 (32%) and 17 (70%) patients showed high\u2010risk cytogenetics and\/or 1q+, respectively. The overall response rate was 31%. The median duration of response was 13.1 (range 2.8\u201322.0) months. Median progression\u2010free survival rate was 3.4 (range 0.5\u201324.6) months, Overall, the treatment was well tolerated. The combination of ruxolitinib and methylprednisolone demonstrated significant clinical activity among previously heavily\u2010treated MM patients, and responses were achieved among patients who had high\u2010risk cytogenetics. This is the first clinical study to show activity of JAK inhibitors in combination with steroids for MM patients and expands the potential use of these drugs to those with cancers other than myeloproliferative neoplasms.<\/jats:p>","DOI":"10.1111\/bjh.18593","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T08:20:09Z","timestamp":1670574009000},"page":"722-730","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1111","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"first","affiliation":[{"name":"Institute for Myeloma and Bone Cancer Research  West Hollywood California USA"},{"name":"Oncotherapeutics  West Hollywood California USA"},{"name":"Berenson Cancer Center  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Martinez","sequence":"additional","affiliation":[{"name":"Oncotherapeutics  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahmineh","family":"Safaie","sequence":"additional","affiliation":[{"name":"Oncotherapeutics  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders  Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghao","family":"Yang","sequence":"additional","affiliation":[{"name":"Global Oncology  Alhambra California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Moezi","sequence":"additional","affiliation":[{"name":"Cancer Specialists of North Florida  Fleming Island Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lim","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Samuel Oschin Cancer Center  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrooz","family":"Eshaghian","sequence":"additional","affiliation":[{"name":"Compassionate Oncology Medical Group  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Swift","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Eades","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Regidor","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Kim","sequence":"additional","affiliation":[{"name":"Oncotherapeutics  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Kim","sequence":"additional","affiliation":[{"name":"Oncotherapeutics  West Hollywood California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Vescio","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Samuel Oschin Cancer Center  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.913024"},{"issue":"4","key":"e_1_2_10_5_1","article-title":"The role of JAK2 inhibition in polycythemia vera. Target","volume":"7","author":"Mascarenhas J","year":"2018","journal-title":"Oncologia"},{"key":"e_1_2_10_6_1","volume-title":"JAKAFI (ruxolitinib) [package insert]","year":"2021"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201010\u2010812701"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201019\u20101899"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3066"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16158"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010019\u201003595\u20100"},{"issue":"9","key":"e_1_2_10_12_1","first-page":"500","article-title":"The role of JAK inhibitors in multiple myeloma","volume":"17","author":"Ghermezi M","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2114.2114"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17282"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14801"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100331\u20106"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3071"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.013"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.022"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.004"},{"key":"e_1_2_10_23_1","unstructured":"AbbVie.RINVOQ (upadacitinib) extended\u2010release tablets for oral use. Initial U.S. approval: 2019. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s004lbl.pdfRevised 1\/2022. Accessed 6\/22\/2022.10."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010022\u201003335\u20107"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201007\u2010659656"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2005.05509.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004332"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201029754\u2010y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1970218"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01338\u20106"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16176"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:30:39Z","timestamp":1692361839000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/bjh.18593"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18593","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"2022-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}